Lunaphore and Visiopharm Announce New Partnership to Offer Spatial Biology Research Solution With Deep Learning Technology
4.5.2022 18:00:00 EEST | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Visiopharm, a company developing A.I.-driven precision pathology software, today announced a new partnership that will unite staining and imaging with A.I. analysis capabilities. Under the partnership, the companies will co-market a complete end-to-end solution that offers hyperplex immunofluorescence staining, image acquisition, and subsequent analysis with deep learning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005730/en/
The combined offering will include Lunaphore’s COMET™, which can perform automated, hyperplex immunofluorescence staining and imaging, and Visiopharm’s Oncotopix® Discovery, an easy-to-use deep learning solution for tissue-based cancer research. COMET™ and Oncotopix® Discovery are compatible natively, and the combined offering provides an all-encompassing, interoperable spatial biology and data analysis solution for researchers.
Visiopharm is a world leader in A.I.-driven precision pathology software with over two decades experience pioneering innovation in digital pathology and partnering with the most recognized names in tissue-based disease research. With the launch of Oncotopix® Discovery, the most robust version of their respected research image analysis software platform to date, Visiopharm brings the power of deep learning to all. Oncotopix® Discovery allows any scientist, not just image analysis experts, to use their understanding of tissue morphology to train an A.I. deep learning APP to get accurate and reproducible data. The software also features the Multiplex Phenotyping module, an essential tool for investigating the tumor microenvironment revealed by staining platforms such as Lunaphore’s COMET™.
“The technology for staining and imaging multiplexed images is improving rapidly. However, the challenge is how to make sense of what is there,” says James Mansfield, Senior Vice President, Research Business Development at Visiopharm. “How do we interpret highplex staining in a way that not only reveals meaningful insights but does so accurately and reproducibly? That has been our focus from the beginning in developing our Multiplex Phenotyping module. We give researchers a beginning-to-end solution to create a cell phenotype map of the tissue microenvironment and then a set of helpful visualization tools like t-SNE plots and matrixes to verify and interpret the data.”
“That is where we see a powerful synergy between Visiopharm and Lunaphore,” Mansfield continued. “We are both interested in arming researchers with tools to conduct spatial biology analysis that deliver reproducible results. This is essential for true advancement to be made in both basic and especially translational studies.”
With superior tissue profiling capabilities, the COMET™ platform allows a multiplex analysis of up to 40 separate spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications across immuno-oncology, neuroscience, and infectious diseases.
“Our partnership with Visiopharm allows us to create a unified technology solution that can enhance our understanding of cancer pathology,” said Déborah Heintze, Chief Marketing Officer of Lunaphore. “By combining our leading spatial biology platform with Visiopharm’s deep learning capabilities, this collaboration can make it easier for laboratories to adopt and integrate spatial biology solutions for their research.”
To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
To learn more about Oncotopix Discovery, please visit: https://visiopharm.com/oncotopix-discovery/
To learn more about Visiopharm, please visit: https://visiopharm.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
About Visiopharm
Visiopharm® is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, Netherlands and United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005730/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Michelle Oswald
Marketing Manager, Research
Email: mos@visiopharm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization18.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced an expanded strategic partnership with American Digital Corporation to give SAP licensees a lower-risk, more flexible path to cloud modernization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118330258/en/ Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization Through the expanded relationship, American Digital will serve as a solution partner for Rimini Cloud™ for SAP, helping SAP ECC and S/4HANA licensees move their existing SAP systems to modern cloud infrastructure without requiring ERP reimplementation or conversion of perpetual licenses to subscriptions, while maintaining greater control over their long-term roadmap. The announcement builds on a strategic alliance establish
Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 16:00:00 EET | Press release
Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118877583/en/ Sila, a leading battery technology and materials company, today announced a comm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
